JE
AZN icon

JMAC Enterprises’s AstraZeneca AZN Stock Holding History

JMAC Enterprises’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,379
Closed -$330K – 174
2023
Q1 		$330K Hold
2,379
– – 0.08% 139
2022
Q4 		$323K Hold
2,379
– – 0.09% 138
2022
Q3 		$261K Buy
+2,379
New +$302K 0.07% 153

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JMAC Enterprises's AZN Position: Q2 2023 in Review

JMAC Enterprises sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 2,379 shares — an estimated $330K sold.

JMAC Enterprises first reported a position in AZN in Q3 2022 and held it in 3 quarters. The position peaked at $330K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

  • JMAC Enterprises reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
  • JMAC Enterprises sold 2,379 AstraZeneca shares in Q2 2023, an estimated $330K.
  • JMAC Enterprises first reported a position in AstraZeneca in Q3 2022 and held it in 3 quarters.
  • JMAC Enterprises's AstraZeneca position peaked at $330K in Q1 2023.
  • 1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on JMAC Enterprises's 13F filing for Q2 2023, filed 20 Jul 2023.